<DOC>
	<DOC>NCT01589159</DOC>
	<brief_summary>This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.</brief_summary>
	<brief_title>A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>female patients between 18 and 65 years old patients with metastatic breast cancer previousely treated with A/T able and willing to give consent to participate in the study pregnant or lactating females other tumor history instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection concurrent disease or condition that would make the patient inappropriate for study participation resist to participate in the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>